Send entire collection kit (including box) to your central send out location.
Collect
Second-morning, clean-catch voided urine specimen collected in PreservCyt collection vial included in UroCyte Urine Collection Kit (ARUP Supply #41440). Collection kit is available online through eSupply using ARUP Connector contact Client Services at 800-522-2787. For specific instructions refer to Specimen Collection & Handling.
Container
UroVysion FISH Collection Kit
Location
Instructions
HealthPartners
Clinics, Methodist Hospital, Park Nicollet Clinics
HP Warehouse Item; Lawson #5008720
All other locations
ARUP UroVysion FISH Collection Kit via ARUP eSupply #41440
Specimen Preparation
Specimens must be transported in PreservCyt fixative. Acceptable source is voided urine. (Min: 35 mL)
Unacceptable Conditions
Unfixed specimens not in PreservCyt fixative. Frozen specimens. Specimens submitted in expired collection vials.
Storage/Transport Temperature
Ambient or refrigerated
Stability (from collection to initiation)
Ambient: 1 week from collection; Refrigerated: 1 week from collection; Frozen: Unacceptable
Performed
Mon-Fri
Reported
4-14 days
Ordering Recommendations
May aid in diagnosis of urothelial carcinoma and monitoring for tumor recurrence.
Negative: No evidence of numeric chromosomal aberrations associated with urothelial carcinoma identified. Positive: Numeric chromosomal aberrations associated with urothelial carcinoma identified.
Interpretive Data
NEGATIVE results indicate a lack of evidence for the presence of numeric chromosomal abnormalities commonly associated with urothelial carcinoma within the cells collected in this specimen. Negative results in the presence of other symptoms/signs of urothelial carcinoma may suggest the possibility of a false negative test. In this circumstance, additional clinical studies to exclude urothelial carcinoma should be pursued, as clinically indicated. Although this test was designed to detect genetic abnormality associated with most urothelial cancers, there will be some urothelial cancers whose genetic changes cannot be detected by this test.
POSITIVE results indicate the presence of one or more numeric chromosomal abnormalities commonly associated with urothelial carcinoma within the cells collected in this specimen. Positive results in the absence of clinical documentation of urothelial carcinoma within the bladder suggest the possibility of urothelial carcinoma or other urologic malignancy from another site (including ureter, kidney, urethra, and prostate). In this circumstance, further clinical evaluation to exclude these as a source of the abnormal cells is justified.
The UroVysion Bladder Cancer Kit probes were used to detect aneuploidy for chromosomes 3, 7, 17, and/or loss of 9p21 locus via fluorescence in situ hybridization (FISH). Results from this test are intended for use in conjunction with, and not in lieu of, current standard diagnostic procedures, as an aid for initial diagnosis of urothelial carcinoma and for monitoring for tumor recurrence in conjunction with cystoscopy in patients with previously diagnosed bladder cancer.
Methodology
Qualitative Fluorescence in situ Hybridization (FISH)/Computer Assisted Analysis/Microscopy
CPT Codes
88121
Collection
Alias
Epic: LABS20425; ARUP: 3016627
Send entire collection kit (including box) to your central send out location.
Collect
Second-morning, clean-catch voided urine specimen collected in PreservCyt collection vial included in UroCyte Urine Collection Kit (ARUP Supply #41440). Collection kit is available online through eSupply using ARUP Connector contact Client Services at 800-522-2787. For specific instructions refer to Specimen Collection & Handling.
Container
UroVysion FISH Collection Kit
Location
Instructions
HealthPartners
Clinics, Methodist Hospital, Park Nicollet Clinics
HP Warehouse Item; Lawson #5008720
All other locations
ARUP UroVysion FISH Collection Kit via ARUP eSupply #41440
Specimen Preparation
Specimens must be transported in PreservCyt fixative. Acceptable source is voided urine. (Min: 35 mL)
Unacceptable Conditions
Unfixed specimens not in PreservCyt fixative. Frozen specimens. Specimens submitted in expired collection vials.
Storage/Transport Temperature
Ambient or refrigerated
Stability (from collection to initiation)
Ambient: 1 week from collection; Refrigerated: 1 week from collection; Frozen: Unacceptable
Performed
Mon-Fri
Reported
4-14 days
Ordering Recommendations
May aid in diagnosis of urothelial carcinoma and monitoring for tumor recurrence.
Negative: No evidence of numeric chromosomal aberrations associated with urothelial carcinoma identified. Positive: Numeric chromosomal aberrations associated with urothelial carcinoma identified.
Interpretive Data
NEGATIVE results indicate a lack of evidence for the presence of numeric chromosomal abnormalities commonly associated with urothelial carcinoma within the cells collected in this specimen. Negative results in the presence of other symptoms/signs of urothelial carcinoma may suggest the possibility of a false negative test. In this circumstance, additional clinical studies to exclude urothelial carcinoma should be pursued, as clinically indicated. Although this test was designed to detect genetic abnormality associated with most urothelial cancers, there will be some urothelial cancers whose genetic changes cannot be detected by this test.
POSITIVE results indicate the presence of one or more numeric chromosomal abnormalities commonly associated with urothelial carcinoma within the cells collected in this specimen. Positive results in the absence of clinical documentation of urothelial carcinoma within the bladder suggest the possibility of urothelial carcinoma or other urologic malignancy from another site (including ureter, kidney, urethra, and prostate). In this circumstance, further clinical evaluation to exclude these as a source of the abnormal cells is justified.
The UroVysion Bladder Cancer Kit probes were used to detect aneuploidy for chromosomes 3, 7, 17, and/or loss of 9p21 locus via fluorescence in situ hybridization (FISH). Results from this test are intended for use in conjunction with, and not in lieu of, current standard diagnostic procedures, as an aid for initial diagnosis of urothelial carcinoma and for monitoring for tumor recurrence in conjunction with cystoscopy in patients with previously diagnosed bladder cancer.
Methodology
Qualitative Fluorescence in situ Hybridization (FISH)/Computer Assisted Analysis/Microscopy
Laboratories.